BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Core Insights - BioNTech reported strong execution and pipeline momentum in 2025, with significant advancements in its oncology pipeline and a commitment to becoming a multi-product company by 2030 [3][5]. Financial Performance - For the full year 2025, BioNTech generated revenues of €2,869.9 million, an increase from €2,751.1 million in 2024, while the fourth quarter revenues were €907.4 million, down from €1,190.0 million in the same period last year [4][12]. - The company reported a net loss of €1,136.1 million for 2025, compared to a net loss of €665.3 million in 2024, with a diluted loss per share of €4.70, compared to a loss of €2.77 in the previous year [12][14]. - Adjusted net loss for the fourth quarter was €79.5 million, down from a profit of €432.4 million in the same quarter of 2024 [13][15]. Research and Development - R&D expenses for 2025 were €2,104.9 million, a decrease from €2,254.2 million in 2024, attributed to cost savings and active portfolio management [7][8]. - The company plans to focus on late-stage development and commercial readiness in oncology, with adjusted R&D expenses expected to be between €2.2 billion and €2.5 billion in 2026 [19]. Pipeline and Clinical Trials - BioNTech is on track for a catalyst-rich year in 2026, with six late-stage data readouts expected across various therapeutic areas, including immunomodulators and mRNA cancer immunotherapies [5][27]. - The company is advancing its bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned in collaboration with Bristol Myers Squibb [5][27]. Corporate Developments - BioNTech co-founders are establishing an independent company focused on next-generation mRNA innovations, with a management transition expected by the end of 2026 [29]. - The company maintains a strong financial position with cash, cash equivalents, and security investments totaling €17.2 billion as of December 31, 2025 [16][17]. 2026 Financial Guidance - BioNTech anticipates total revenues for 2026 to be between €2.0 billion and €2.3 billion, with lower COVID-19 vaccine revenues expected compared to 2025 [18]. - Adjusted SG&A expenses for 2026 are projected to be between €700 million and €800 million [19].